Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US

Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025DTP offering to expand to other appropriate products; ...
TipRanks on MSN

Novartis to launch direct-to-patient platform for Cosentyx in U.S.

Novartis (NVS) announced plans to launch a direct-to-patient platform in the U.S. which will come into effect on November 1, offering cash-paying ...
Managed Healthcare Executive

Novartis to Offer Cosentyx to Cash Paying Patients at a 55% Discount

Novartis said that it is exploring an additional direct-to-employer model to increase access and affordability for cash-paying patients in the United States.
TMCnet

New ixlayer Survey Finds 73% of Pharma Leaders Are Running or Planning to Launch a DTP Program in the Next Year, and Half Say DTP Will Be Standard Practice Within Five Years

"This survey found that half of pharma leaders believe DTP will be standard practice within five years. That's not a far-off future–that's tomorrow. The companies that adapt their playbooks now will ...